An Observational Study of the Use and Safety of Xolair During Pregnancy (EXPECT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2015 by Genentech, Inc.
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: September 5, 2006
Last updated: April 3, 2015
Last verified: April 2015
The Xolair Pregnancy Registry is an observational study established by Genentech to obtain data on pregnancy outcomes in women who are exposed to Xolair. Women exposed to at least one dose of Xolair within 8 weeks prior to conception or at any time during their pregnancy will be followed to completion of their pregnancies. The evaluation of infants will be conducted at birth and at 6-month intervals until infants are 12 months old.

Condition Phase
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Xolair Pregnancy Registry: An Observational Study of the Use and Safety of Xolair (Omalizumab) During Pregnancy

Further study details as provided by Genentech, Inc.:

Estimated Enrollment: 250
Study Start Date: October 2006
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Enrollment in the Xolair Pregnancy Registry is voluntary and must be initiated by the pregnant woman. A healthcare provider (HCP) cannot enroll a patient but can suggest that the pregnant woman call the Registry Center to enroll herself.
Eligibility for enrollment is based on Xolair exposure in women, whether inadvertent or deliberate, in relation to pregnancy. Women who have been exposed to at least one dose of Xolair within 8 weeks prior to conception or during pregnancy may be included in this registry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00373061

Contact: Trial Information Support Line 866-496-5247 ext 3

United States, California
Genentech Trial Information Support Line Recruiting
South San Francisco, California, United States, 94080
Contact    866-496-5247 ext 3      
Sponsors and Collaborators
Genentech, Inc.
Study Director: John Thorp, M.D. PPD
  More Information

No publications provided

Responsible Party: Genentech, Inc. Identifier: NCT00373061     History of Changes
Other Study ID Numbers: Q2952g
Study First Received: September 5, 2006
Last Updated: April 3, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Genentech, Inc.:
Expect processed this record on November 27, 2015